| Autor: |
Raguindin, Ricky Kristan M., Mercado, Candy C. |
| Předmět: |
|
| Zdroj: |
AIP Conference Proceedings; 2022, Vol. 2440 Issue 1, p1-18, 18p |
| Abstrakt: |
Traditional cancer treatments lacking specificity and understanding about their cancer-targeting mechanisms can be addressed by developing a prodrug with targeting and imaging functionalities. Folic acid (FA) adsorbed on chitosan (CS)-encapsulated melphalan (MELPH) and coumarin 343 (C343) or FA-CS-MELPH-C343 is synthesized as micro-composite beads. By encapsulating MELPH, its cytotoxicity is decreased. UV absorption indirectly determines the extinction coefficient of MELPH. During the 30-minute encapsulation, 8% MELPH degradation and 42% encapsulation efficiency are observed. Negligible in vitro MELPH release is recorded within an hour and a maximum of 16% release occurs after four hours. C343 encapsulation is 50% efficient with maximum in vitro release of 1.4% after four hours. FA adsorption/desorption are both described by Ho-McKay pseudo-second order. Moreover, the microbead zeta potential reveals their moderate stability. Due to the encapsulation, release mechanism, fluorescence, and biocompatibility, FA-CS-MELPH-C343 exhibits potential in theranostics. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
